UNSPSC 51342311: Aciclovir sodium

This classification denotes a purine antagonist and antiviral agent with the molecular formula C8H10N5O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 927L42J563, chemically known as 6h-purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)-, monosodium salt but more generally known as aciclovir sodium, which bears US NIH Compound Identifier 50600. The base compound, Aciclovir, also known as acyclovir, also comes in base and natrium forms.

European Medicines Agency schedules Aciclovir sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00284MIG. Most nations, for tariff and trade purposes, schedule aciclovir sodium under HS 29335995. SMILES: C1NC2C(=O)[N-]C(NC2N1COCCO)N.[NA+].

UNSPSC 51342311 Aciclovir sodium is a Commodity code that represents a specific antiviral pharmaceutical product, but the recent state and local solicitations tagged under this code do not align with aciclovir procurement — they instead cover naloxone, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency responders, and generic multi-source pharmaceuticals through cooperative purchasing. The mismatch suggests that either the code has been applied inconsistently by issuing bodies or the opportunities represent broader pharmaceutical procurement where aciclovir may be included as one line item among many. State and local buyers appear to use this code — or codes near it in the pharmaceutical taxonomy — when acquiring pharmaceutical products through competitive processes, but the recent posting activity shows no discrete aciclovir solicitations. Instead, opportunities span county health departments, state health and human services agencies, municipal fire departments, and multistate cooperative purchasing alliances.

Geographic activity centers on Florida and the upper Midwest, with the most recent opportunities originating from Seminole County, Florida (naloxone and drug deactivation systems, IFB, due July 26, 2023), Texas Health and Human Services Commission (direct-to-manufacturer prescription RFI, April 2026), City of Tampa (medical and first aid supplies for fire rescue, IFB, due March 13, 2026, $700,000 estimated contract with Small Local Business Enterprise set-aside), and the Minnesota Multistate Cooperative Purchasing Alliance covering Minnesota, Oregon, and other participant jurisdictions (generic multi-source pharmaceuticals and OTC products, RFP, due March 26, 2026). The code shows little relevant recent activity for aciclovir as a standalone product line; firms pursuing this commodity should verify whether state and local buyers are specifically sourcing aciclovir through dedicated solicitations or including it within broader pharmaceutical and medical-supply contracts.